Servier Advances Promising Eye Cancer Treatment, Darovasertib, Towards Potential 2026 Launch
PARIS – Servierโค is poised too initiate a โglobal Phase III clinical trial in 2026 evaluatingโฃ Darovasertib, โฃa potential new treatment for uveal melanoma, a โrare and aggressiveโค eye cancer. The trial, conducted in partnership with โIdeaya, will focus on adjuvant therapy following primary tumor removal – a critical area currently lacking effective options.
Darovasertib, โwhich already holds FDA Fast Track โ designation, is โขcurrently undergoing evaluation in multiple โclinical settings, including as a monotherapy and in combination with Crizotinib, for both primary andโ metastatic forms of the disease, and across patient populations with and without specific cancer-promoting โmutations. Results from these trials are โฃanticipated in 2025 and โฃ2026.
Servier anticipatesโข limited competition โshouldโ Darovasertib prove prosperous. Existing treatments like โขimmunocore’s Kimmtrak (Tebentafust), approved โคforโ metastatic forms, have a narrower scope. A successful launch couldโค command a high โmarket price, perhaps generating tensโข of millions of euros in annual โฃrevenue for Servier’s growing oncology portfolio. Immunocore generatedโฃ $310 million in 2024 from Kimmtrak โขsales.While Servier will not โhold American rights to Darovasertib, the company plans to market the treatment in Europe and the rest of the world.
This development aligns with Servier’s strategic focus on rare and arduous-to-treat cancers. The company recently secured European approval for โขVoranigo, a โฃtreatment โขfor diffuse glioma, andโ expandedโฃ its oncology pipeline through agreements withโข Black โDiamond and Bionova.โข The potential sale of Biogaranโ to โBC Partners โฃcould further fuel investment in the therapeutic area.
Servier’s oncology divisionโข currently represents โฌ1.4 billion โฃin annual sales for the โFrench pharmaceutical company.
